Arthritis drug improves survival odds for COVID-19 patients treated with remdesivir by 35%, NIH study finds An NIH trial tested a combination of Eli Lilly’s arthritis drug, barcitinib, and the antiviral  remdesivir to treat COVID-19  Overall, those who got both drugs were 35% more likely to survive than those given remdesivir alone  People on supplemental